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Heat shock protein 27 (hsp-27) is a regulator of oestrogen receptor (ER) expression and a modulator of intracellular homeostasis. In
this laboratory, Shaaban et al demonstrated the importance of ER-a, together with Ki67, in enhancing the progression of benign
breast lesions of defined morphological types. To better understand the mechanisms by which ER-a promotes breast neoplasia, this
study was performed to test the hypothesis that the roles of ER-a and hsp-27 may be defined by their quantitative expression in
proliferative breast lesions of varying histological risk. The expression of hsp-27 was identified using a specific monoclonal antibody
and analysed to assess the proportion of positive epithelial cells using digitised morphometric image analysis. The expression of ER-a
was analysed by immunohistochemistry and Western blotting in a variety of benign (HUMA121) and malignant mammary cell lines,
including ER-a(þ) (MCF7, ZR-75, T47D) and ER-a( ) (MDA-MB 231) breast cancer cell lines. The data confirm that, during
progression from normal through proliferative breast lesions to in situ cancer, there was a significant increase in both the proportion
and the optical density of the epithelial cells expressing hsp-27. The mean levels of expression ranged from 7.4% of the total number
of epithelial cells in normal lobules to 25.17% of epithelial cells in hyperplasias of usual type (HUT) to 61.1% of epithelial cells in ductal
carcinoma in situ (Po0.001). The study has confirmed the expression of hsp-27 to be closely associated with ER-a(þ) expression,
and that its regulated expression occurs early along the mammary oncogenic pathway, supporting the initial hypothesis. It is our
proposal that the differential expression of hsp-27 modulates the phenotypic behaviour of morphologically benign epithelial cells and
hence may be an important determinant in initiating, or promoting, a population of human mammary cancers.
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There are several distinct routes by which human breast cancers of
ductal type are believed to develop (Shaaban et al, 2002a,c). One
such putative pathway, from normal to invasive carcinomas,
occurs through the morphological intermediaries of nonatypical
hyperplasia (hyperplasia of usual type, HUT) and atypical ductal
hyperplasia (ADH) to ductal carcinoma in situ (DCIS). The relative
risk of ductal carcinoma arising in these lesions increases at each
stage (Lakhani, 1999). One possible approach to understanding the
mechanisms involved in mammary carcinogenesis is by comparing
the expression of putative markers of risk in morphologically
normal, precancerous and malignant lesions. In this respect,
oestrogen-associated proteins are of particular interest since this
hormone plays a crucial role in regulating mammary epithelial
proliferation (Buerger et al, 2001), and is recognised as promoting
the malignant progression of certain neoplastic and potentially
premalignant lesions (Page and Dupont, 1990). Important
modulators of oestrogen, and likely mediators of this hormone’s
effect on breast epithelial cells, act through different receptors,
including the family of homeostatic regulators known as heat
shock proteins (hsp’s) (Kato et al, 2000).
A wide range of pathophysiological influences regulate the
expression of hsp’s in normal physiology as well as in a variety of
pathological conditions. Categories of proteins within the overall
family of hsp’s have been classified, according to their relative
molecular mobility (Mr) on gel electrophoresis. In mammals, these
comprise hsp’s-100, -90, -70, -60 and the small molecular weight
proteins (Coffer et al, 1985). The oestrogen-regulated protein
known as hsp-27 was initially identified in breast epithelial MCF-7
cells (Edwards et al, 1980; Conroy and Latchman, 1996). The gene
for this protein is known to produce a number of splice variants
from a single gene, encoding at least 13 different protein isoforms.
The expressed isoforms have multiple complementary functions,
including the regulation of translational initiation and thereafter
chaperone activity. Thus, the protein has an important role in
maintaining intracellular protein homeostasis. The protein acts as
a molecular chaperone and allows cells to survive damage from a
variety of insults that may be otherwise lethal (Jakob et al, 1993).
Thus, the modulated regulation of apoptosis might be a potentially
important mechanism by which hsp-27 is permissive for, or
promotes, breast carcinogenesis.
Previous work in this laboratory has confirmed hsp-27 to be an
independent predictor of clinical outcome in prostate cancer
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y(Cornford et al, 2000). That study found in situ neoplastic
transformation of prostatic epithelium to be associated with
transient loss of hsp-27 expression. The subsequent re-expression
of hsp-27 occurred in some, but not all, invasive cancers where the
quantitative level of hsp-27 expression correlated with Gleason
grade, and was independently predictive of poor clinical outcomes.
While the precise mechanisms remain uncertain, and are being
elucidated, it is recognised that the modulated expression of ER
and the initiation of apoptosis are important factors in the
promotion of prostate cancer. Such a mechanism may also play a
role in breast cancers, another hormone-dependent neoplasm of
glandular epithelium.
While there has been considerable interest in the potential role
of hsp-27 in advanced breast cancer (Thor et al, 1991), little is
known about its expression in early breast lesions, particularly
those now recognised to be associated with abnormal ER-a
expression. A previous study by Ciocca et al (1983) described
the expression of hsp-27 in a small number of normal breast
tissues (n¼7) and fibroadenomas (n¼5). One further study has
assessed the pattern of immunostaining of hsp-27 (also called 24-
kDa protein) in a range of benign breast biopsy specimens and
showed little or no staining in ducto-lobular tissue or fibroade-
noma, but high levels of staining in apocrine metaplasia (Courtney
et al, 1990). However, no previous studies have assessed the
expression of hsp-27 in a large number of benign, preneoplastic
and malignant breast lesions, using digitised image analysis to
clarify its association with mammary neoplastic transformation.
Nor has there been any previous detailed analysis of hsp-27
expression in benign or malignant mammary cell lines.
Therefore, the objective of this study was to define and compare
the level of expression of hsp-27 in morphologically benign breast
lesions of increased risk with that in malignant breast lesions.
Since hsp-27 is an oestrogen-regulated protein, and the progres-
sion of particular abnormal breast lesions is now recognised to be
oestrogen-associated (Shaaban et al, 2002b), a further objective
was to determine whether there is a demonstrable association
between hsp-27 and oestrogen receptor (ER) expression in those
lesions of increased risk.
MATERIALS AND METHODS
Patients and specimens
All patients analysed in this study were diagnosed with benign or
malignant breast disease in the Department of Cellular and
Molecular Pathology at the Royal Liverpool University Hospital,
during the 20-year period 1979–1999. Within the group of benign
disease, 36 patient specimens contained 123 foci of HUT. An
additional 31 patient specimens contained 118 foci of DCIS, with
an associated invasive component. Patients diagnosed with breast
cancer (n¼69) between 1993 and 1995, who had donated tissues to
the Cancer Research Tissue Bank, had 345 foci of invasive ductal
carcinoma, as defined by analysis of five high-power fields using
image analysis. Each focus was analysed individually. Normal
breast tissues from patients undergoing reduction mammoplasty
(n¼29), continued in 73 areas of morphologically normal tissue,
was submitted to detailed analysis. These data are presented in
Table 2. In addition, and separately during this same time period,
there were 52 cases of benign nonproliferative disease comprising
apocrine metaplasia (27), blunt-duct adenosis (19), sclerosing
adenosis (7), fibroadenomas (5) and papillomas (3). The details of
these cases are included in Table 3.
The histological preparations from all cases were reviewed
independently by three investigators (PAO’N, AMS and CSF) before
a consensus agreement was obtained to confirm the diagnosis and
to clarify the benign and malignant lesions, according to the
pathology guidelines of the UK NHS Breast Screening Programme
(Sannino and Shousha, 1994).
Tissue immunohistochemistry
Antibodies Human hsp-27 was identified using a specific anti-
hsp-27 mouse monoclonal antibody (Novocastra, Newcastle-upon-
Tyne, UK) at a dilution of 1:20. ER-a was identified using a mouse
monoclonal anti-ER-a antibody (clone 1D5, Dako Ltd., Ely,
Cambridge, UK) at a dilution of 1:30. Both antibodies were
diluted in Tris-buffered saline (TBS) comprising 50mM Tris (pH
7.4) containing 8% (wv
 1) NaCl and 5% (wv
 1) bovine serum
albumin.
Immunostaining methods
Immunostaining was performed using the standard technique
previously described (Cornford et al, 2000). Paraffin wax-
embedded tissue sections were dewaxed with xylene, rehydrated
through graded ethanols followed by blocking of endogenous
peroxidase activity in H2O2/methanol for 12min. For hsp-27 and
for ER-a immunohistochemistry, antibody-binding epitopes were
retrieved by pressure-cooking tissue sections for 2.5min and then,
after cooling to room temperature, incubating sections with the
appropriate antibody for 40min. After washing twice with TBS,
slides were incubated with sheep anti-mouse immunoglobulin
(Dako, Envision) for 30min. Sections were then washed twice
before immersion in a solution of DAB (2mgml
 1) in phosphate-
buffered saline (PBS) (pH 7.4) for 10min. All incubations were
performed at room temperature. Washes with TBS were performed
between each step. Nuclei were counterstained with Meyer’s
haemalum before mounting slides in DPX.
Controls
Negative immunohistochemical controls were included by per-
forming identical immunohistochemical procedures, but substi-
tuting irrelevant nonimmune serum for the primary antibody.
Three different prostatic carcinomas of varying intensities of hsp-
27 expression were used as positive controls in each batch of
staining. Three ER-a(þ) breast carcinomas were similarly used as
positive controls.
Assessment of immunostaining
Heat shock protein 27 For each case of invasive cancer, the
number of positively stained epithelial cells was estimated visually
Table 1 Characteristics of mammary cell lines included in the study
Cell line Origin Morphology ER-a status Reference
HUMA121 Benign breast disease
a Epithelial Negative Rudland et al (1993)
MCF7 Breast carcinoma Epithelial Positive Soule et al (1973)
ZR-75 Breast carcinoma Epithelial Positive Engel et al (1978)
T47D Breast carcinoma Epithelial Positive Westley and Rochefort (1980)
MDA-MB 231 Breast carcinoma Myoepithelial-like Negative Cailleau et al (1974)
aParent cell line: HMT3522 (Rudland et al, 1993).
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yby scanning the entire tissue at low power using conventional light
microscopy. At least five high-power fields per case were analysed
and expressed as a percentage of the total epithelium present. The
mean percentage was calculated for every case. Initially, for control
normal tissue sections, together with any benign changes or DCIS,
the percentage of positively stained cells was counted for each type
of focus and then averaged to give a mean percentage per case.
All tissue sections assessed visually were submitted to digitised
image analysis to measure the mean optical density (OD) of
staining. Prior to each set of measurements, and at intervals during
each session, the optical system was calibrated using standard
slides. On each occasion, the microscope was calibrated using iden-
tical parameters and the OD of the standard slide was recorded.
For all control normal tissues, for benign lesions and for DCIS,
each focus was individually assessed and the OD averaged for each
case. For invasive cancers, the OD of immunostained malignant
cells was assessed on five high-power fields and the mean number
of positive cells calculated for each case.
Oestrogen receptor-a The percentage of stained epithelial cells
was calculated as a proportion of the total number of epithelial
cells present on the slide. A 10% cut-off was applied as the
criterion to define positive staining for invasive cancers (Sannino
and Shousha, 1994), also conforming to our previous studies
(Shaaban et al, 2002a).
Epithelial cell lines
Cell lines employed in this study, and their properties, are
summarised in Table 1. HUMA121 was supplied by Professor P
Rudland, University of Liverpool; MCF7 and ZR-75 were supplied
by Mr M Shaw, ICI Pharmaceuticals Ltd., Macclesfield; T47D was
supplied by Professor I Keydar, Faculty of Life Sciences, University
of Tel Aviv; MDA-MB 231 was a gift from Dr C Green, University
of Liverpool.
Cell culture
Cells were cultured as monolayers in DMEM (Life Technologies,
Inc.) supplemented with 10% (vv
 1) foetal calf serum (Life
Technologies, Inc., Paisley, Scotland), 1mM glutamine, 100IUml
 1
penicillin G and 100IUml
 1 streptomycin in an atmosphere of 5%
CO2 in air at 100% humidity and 371C. The T47D cell line was
supplemented with insulin at a concentration of 1mgml
 1. Media
were changed on alternate days.
Immunohistochemistry of cell lines
The expression of hsp-27 by human benign mammary cell
line HUMA121 (Rudland, 1987), ER-a(þ) breast cancer cell
lines (MCF7, ZR-75, T47D) and ER-a( ) breast cancer cell line
(MDA-MB 231) was analysed by immunohistochemistry: Mono-
layered cultures and cell blocks were prepared from the five cell
lines. Monolayered cultures were obtained by allowing cells to
grow on sterile glass slides until subconfluent and then fixed by
immersion in 95% (vv
 1) methanol for 5min. Paraffin-wax-
embedded cell blocks were prepared from 2% (wv
 1) agar using
the following protocol: After trypsinisation, cells were washed with
two changes of PBS (20mM, pH 7.2), followed by scraping using a
rubber policeman followed by centrifugation at 2500rpm for
3min. Cells were then fixed overnight using 10% (vv
 1) buffered
formal saline, followed by centrifugation at 2500rpm for 10min.
After discarding the supernatant, molten agar was added to the cell
pellet, which was centrifuged and allowed to solidify at 41C. The
pellet was processed routinely and embedded in paraffin-wax
blocks. Sections were cut at 5mM and stained immunohistochemi-
cally for hsp-27. Smears were stained manually using the identical
hsp-27 antibody, but without antigen retrieval. Washings were
performed between all stages of the procedure using TBS-Tween.
Gel electrophoresis and Western blotting
The expression of hsp-27 by human benign mammary cell line
HUMA121 (Rudland, 1987), ER-a(þ) breast cancer cell lines
(MCF7, ZR-75, T47D) and ER-a( ) breast cancer cell line (MDA-
MB 231) was analysed by polyacrylamide gel electrophoresis and
Western blotting: Cell lysates were prepared in a buffer comprising
10mM Tris (pH 6.8) containing 0.5% sodium deoxycholate, 0.02%
sodium azide, 20% (vv
 1) glycerol, 0.5% Triton X-100 and
100mgml
 1 phenylmethylsulphonyl fluoride (PMSF). Initially,
0.5ml of lysis buffer was spread over each 9-cm culture plate of
cells, incubated for 15min to obtain cell lysis before the cells were
scraped to one edge of the plate and aspirated into a microfuge
tube. The lysate was centrifuged at 3000rpm for 10min. The
supernatant was aspirated and transferred to a fresh microfuge
tube. The protein concentration of the supernatant was measured
using the Bradford assay (Bio-Rad Laboratories Ltd., Hemel
Hemstead, UK). Equal amounts of protein (20mg per lane) were
separated by 12% (wv
 1) SDS/PAGE. To verify that equal amounts
of proteins were loaded in the stacking gels, the actin expression
was estimated in each lane using a rabbit polyclonal anti-actin
antibody (Santa Cruz Biotechnology, Inc., UK). After separation,
proteins were transferred onto nitrocellulose membranes by
electroblotting. Thereafter, blots were blocked by immersion at
room temperature for 1h in ProtoBlock solution (National
Diagnostics Inc., UK) and probed with the identical antibody
used for immunohistochemistry and at the same dilution. After
three 15-min washes in 10mM Tris-buffer (pH 7.5), blots were
incubated with peroxidase-conjugated secondary antibodies. The
enhanced chemiluminesence Western blotting analysis system
(Amersham Life Science) was used for protein detection. Blots
were repeated twice to confirm the data.
Statistical methods
All data were analysed by Spearman’s rank correlation coefficient
(r) using SPSS software for Windows (release 10.0). Fisher’s z-
transformation test was used to compare any pair of correlation
coefficients. Student’s t-test was used to compare the means of the
percentage expression and optical density among the different
groups. Pp0.05 was used to define statistical significance.
RESULTS
Heat shock protein 27
Control normal epithelium All control normal specimens ex-
pressed hsp-27 by some cells in each case. However, the expression
of hsp-27 was heterogeneous within these tissues. A wide variation
Table 2 hsp-27 expression (mean % and mean OD) in normal, benign
and malignant breast
Lesion
Cases
(n)
Foci
(n)
Mean %
positive cells (7s.d.)
Mean
O.D.7s.d.
Normal 29 73 7.40711.8 0.3470.22
HUT 36 123 25.17724.68
a 0.5070.23
b
DCIS 31 118 61.10731.47
c 0.6370.18
d
IC 69 345 58.87736.5
e 0.5670.12
f
aHigher than normal Po0.001.
bHigher than normal P¼0.008.
cHigher than HUT
P¼0.008 and normal Po0.001.
dHigher than HUT P¼0.01 and normal Po0.001.
eLower than DCIS P¼0.62, higher than HUT (Po0.001) and higher than normal
(Po0.001).
fLower than DCIS P¼0.22 , higher than HUT(P¼0.596)and higher than
normal (Po0.001). HUT¼hyperplasia of usual type. DCIS¼ductal carcinoma in situ.
IC¼invasive carcinoma I.
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within adjacent foci (Table 2). The distribution of hsp-27 was
predominantly cytoplasmic and diffuse, although occasionally
there was granularity of the cytoplasm and/or staining of plasma
membranes (Figure 1A). The mean proportion of epithelial cells
expressing hsp-27 was 7.4% with a mean OD of 0.32. A strong
positive correlation was found between the mean percentage of
epithelial cells expressing hsp-27 and the corresponding OD of its
expression (r¼0.505, P¼0.005).
Benign epithelium – nonproliferative lesions In all these lesions,
expression occurred within the epithelium, with no staining of the
stroma. These data are summarised in Table 2. In all cases of
epithelial apocrine metaplasia, hsp-27 was consistently expressed
within the cytoplasm (Figure 1B). In Blunt duct adenosis (BDA)
(Table 3), hsp-27 was expressed in most foci where it occurred
predominantly within the cytoplasm of epithelial cells, character-
istically localised to apical cytoplasmic ‘snouts’ (Figure 1C).
Sclerosing adenosis (Figure 1D), papillomas (Figure 1E) and
Figure 1 Patterns of hsp-27 expression in different breast lesions: (A) hsp-27 expression in normal terminal duct lobular unit showing scattered positive
cells. Note that the expression is cytoplasmic with no nuclear staining. (B) Consistently high level of expression in apocrine metaplasia with negative staining
of adjacent normal ducts. (C) BDA showing cytoplasmic staining with characteristic apical localisation within cytoplasmic snouts. (D) hsp-27 expression in
sclerosing adenosis showing heterogeneity in % and intensity of staining. (E) Staining in papilloma is localised to the epithelium with no expression in the
stroma. (F) hsp-27 expression in HUT consisting of more frequent positively stained epithelial cells than in normal lobules. (G) DCIS with a large number of
strongly stained cells. (H) Uniformly strong positive staining in invasive cancer with adjacent nonstained normal duct.
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epithelial component.
Benign epithelium – hyperplasia of usual type The mean
percentage of hsp-27 expression (25.17724.68) was higher in
HUT (Figure 1F) when compared with normal foci (Po0.001), as
was the mean OD of staining (P¼0.008).
Malignant epithelium The mean percentage of hsp-27 expression
was higher in DCIS (Figure 1G) when compared with HUT
(Po0.001; Figure 2). Similarly, the mean optical density (OD) of
hsp-27 was significantly increased from HUT to DCIS (P¼0.01;
Figure 3). However, no significant difference was identified in
either the proportion of cells expressing hsp-27 or the OD of
staining when comparing low-grade DCIS (n¼16) with high-grade
DCIS (n¼15). Also, there was no significant difference in the
mean percentage of hsp-27 expression by epithelial cells or mean
OD of staining between DCIS and invasive cancer (Table 2).
With respect to intercellular distribution, heterogeneity was a
feature of staining commonly observed within invasive cancers
(Figure 1H), with some cases containing intensely stained regions
immediately adjacent to negative regions. A strong positive
correlation was found between the mean proportion of cells
expressing hsp-27 and the OD of staining in normal lobules
(r¼0.505, P¼0.005), HUT (r¼0.679, Po0.001) and invasive
cancers (r¼0.646, Po0.001). However, none of these values for ‘r’
between the groups was significantly different from one another.
Oestrogen receptor-alpha (ER-a)
Control normal epithelium In normal lobules, ER-a(þ) cells
were less interspersed among a majority of nonstained cells. The
mean percentage of ER-a expression in normal breast lobules was
22.84 (716.69). No correlation was found between ER-a expres-
sion and either percentage of epithelial cells expressing hsp-27 or
the OD of hsp-27 staining (Table 4).
Benign epithelium – nonproliferative lesions The expression of ER-
a was not analysed in this group since their risk of progressing to
breast cancer is low, and has not been quantified. Furthermore, some
of these lesions (e.g. apocrine metaplasia) are known to be ER-a( ).
Benign epithelium – hyperplasia of usual type In HUT, the mean
percentage of ER-a was 41.62 (724.19; Table 4). A significant
positive correlation was found between the proportion of cells
expressing ER-a and with both the proportion of cells expressing
hsp-27 (P¼0.016) and the OD of hsp-27 staining (P¼0.035).
Malignant epithelium The mean percentage of ER-a expression
in DCIS and invasive carcinoma was 58.01 (741.64) and 57.52
(738.89), respectively (Table 4). In both types of lesions, there was
a highly significant correlation between hsp-27 expression and OD
as well as between hsp-27 expression and ER-a status (Po0.0001)
and the proportion of ER-a(þ) cells (Table 4). The mean OD of
hsp-27 staining (0.611) was significantly higher in ER-a(þ)
tumours when compared with ER-a( ) tumours (0.514,
Po0.0001). Comparison between the values of ‘r’ in normal
lobules and HUT, using Fisher’s z-transformation, revealed a
difference that almost reached significance (P¼0.07). A similar
comparison between normal lobules and invasive cancers con-
firmed a difference that was statistically significant (P¼0.04).
However, no statistically significant difference was found on
comparing values of ‘r’ for HUT and invasive cancer (P¼0.9).
Immunohistochemistry of cell lines When compared with benign
cell line HUMA121, a strikingly higher expression of hsp-27
occurred in the four malignant cell lines MCF7, ZR-75, T47D and
MDA-MB 231. Moreover, the expression of hsp-27 was strong in
ER-a(þ) cell lines MCF7, ZR-75 and T47D, whereas there was
minimal expression by ER-a( ) cell line MDA-MB 231.
Western blotting of cell lines Mammary cell lines exhibited
marked differences in the hsp-27 expression between the benign
and malignant lines. The benign cell line, HUMA121, did not
express the protein. However, all four breast cancer cell lines
exhibited enhanced expression, particularly ZR-75 and T47D, both
of which are strongly ER-a(þ) (Figure 4).
Table 3 hsp-27 expression in nonmalignant breast lesions
Lesion
Positive
cases (n)
No. of
foci (n)
Positive
cases (%)
Mean % hsp-27
positive cells
Apocrine metaplasia 27 27 100 100
BDA
a 16 19 84.21 47.5
Sclerosing adenosis 4 7 57.14 53
Fibroadenoma 3 5 60 75
Papilloma 2 3 66.67 22
aBDA¼blunt duct adenosis.
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Figure 2 Boxplot graph plotted for the percentage expression of hsp-27
in the normal breast, HUT, DCIS and invasive cancer.
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Figure 3 Boxplot graph plotted for the optical density of hsp-27
immunostaining in the normal breast, HUT, DCIS and invasive cancer.
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yDISCUSSION
This study has extended our previous analysis of the relationship
between ER-a and ER-associated proteins, specifically hsp-27 in
human breast tissues containing morphological lesions of recog-
nised malignant potential as well as in human breast carcinomas.
In this current study, the mean expression of hsp-27 increased
progressively from normal through proliferative breast disease to
in situ cancer. However, there was no significant additional
increase in the expression of hsp-27 from in situ cancer to invasive
malignancy. Our current findings support the hypothesis that the
modulated expression of hsp-27 occurs relatively early along the
oncogenic pathway in mammary epithelial cells. Such alterations
in expression might be an important factor contributing to the
initiation of tumorigenesis. Since there is evidence that the
expression of hsp-27 blocks apoptosis induced by a wide range
of stimuli (Richards et al, 1996) and protects tumour cells against
the apoptotic effects of TNF-a (Wang et al, 1996), a likely
mechanism is by imparting resistance to apoptosis and then by
maintaining those particular populations of epithelial cells of
enhanced malignant potential.
This study has also detailed the pattern of hsp-27 expression in a
range of benign breast lesions, including those suggested by some
authors to carry an increased risk of developing breast cancer
(Dupont and Page, 1985). In apocrine metaplasia (Courtney et al,
1991), the previously reported high expression of hsp-27 has been
confirmed. However, the precise significance of this phenomenon
is still not clear since it is believed that these lesions are ER-( ),
while positive for androgen receptors (Gatalica, 1997). Further-
more, the likelihood of these lesions progressing to malignancy
remains in dispute.
Although the level of expression of hsp-27 now detected in the
various benign lesions is higher than previously reported (Ciocca
et al, 1983), the antibodies employed in these earlier studies are
not identical. Furthermore, current immunohistochemical techni-
ques are more sensitive and more objective than those previously
employed. Using these novel reagents, this current study has
demonstrated for the first time a correlated increase in hsp-27 OD
of staining from normal epithelium through nonatypical epithelial
proliferations to overt malignancy. Thus, the level of expression of
hsp-27 protein, in conjunction with the number of positively
stained cells, might be an important factor relative to the level of
ER-a in determining the outcome of individual benign lesions.
Hsp27 is synthesised under oestrogen control (Edwards et al,
1981a). The protein was originally identified in MCF-7 cells
(Edwards et al, 1981a,b) as well as in primary human breast
carcinomas (Tandon et al, 1990). In cultured human breast cancer
cells, the hsp-27 gene is regulated by oestradiol as well as by heat
shock (Fuqua et al, 1989). Oestrogens increase the transcription of
srp-mRNA by two- to three-fold, whereas antioestrogens decrease
expression in an ER-positive cell line (Thor et al, 1991). Thus,
Hsp-27 may be a component of the ER machinery (Coffer et al,
1985) possibly, as part of a direct feedback loop. This study
has confirmed a close association between hsp-27 and ER-a in
both proliferative epithelium and in established breast cancers.
The finding that hsp-27 expression in the benign mammary cell
line was barely detectable, while remarkably high in malignant
cell lines, strongly supports the data from the intact tissues
in which a progressive increase in hsp-27 expression was identified
to extend from normal through benign to malignant specimens.
In addition, the association between the expression of hsp-27
protein and ER-a protein, both at the cellular and tissue
levels, supports the hypothesis that both proteins interact to
modulate cellular functions. However, this association was not
maintained in normal lobules. These findings support the concept
that hsp-27 is intimately linked to oestrogen action (Adams
and McGuire, 1985; Thor et al, 1991; Kato et al, 2000), although
the exact mechanisms of this link remain poorly understood.
The observation that ER-a(þ) tumours expressed higher levels
of hsp-27, as measured by OD when compared with ER-a( )
cancers, might further suggest a prognostic role for overexpressed
hsp-27 in breast cancer. Quantitative digital analysis of the
intensity of hsp-27 expression, as measured by OD, objectively
enhances the assessment of the percentage expression by
conventional visual methods. Although measurement of the
OD has provided objective quantitative data on the amount of
hsp-27 expressed, which is recognised to be difficult to assess
using light microscopy, its precise significance remains to be
established.
Increased hsp-27 expression in proliferative epithelial lesions
with increased potential of malignant progression, as measured
by percentage expression and OD, as well as its strong association
with ER, might highlight a hormone-dependent pathway of
human mammary carcinogenesis through oestrogen-dependent
overexpression of hsp-27, which protects tumour cells against
apoptosis. Moreover, hsp-27 may also function as a molecular
chaperone in the signal transduction pathways of different cell
regulators (Ciocca et al, 1993), thus enhancing the proposed
mechanism of protection. Further large-scale studies on cohorts
of benign and malignant breast lesions together with long-
term follow-up and detailed molecular analysis will assist in
clarifying the prognostic role and proposed mechanism(s) of
action of hsp-27, particularly as a regulator of ER function, in these
preneoplastic lesions.
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Table 4 Relationship between ER-a and hsp-27 in different breast lesions
Lesion ER-a%(7s.d.) rs (ER-a% and hsp%) P-value rs (ER-a% and hsp OD) P-value
Normal 22.84 (17.69)  0.119 0.573 0.067 0.751
HUT 41.62 (24.19) 0.450 0.016* 0.375 0.035*
DCIS 58 (41.64) 0.824 o0.001** 0.871 o0.001**
IC
a 57.52 (38.89) 0.450 o0.001** 0.254 0.008**
*Significant at Pp0.05. **Significant at Pp0.01.
aIC¼Invasive carcinoma.
Figure 4 Quantitative Western blot analysis of hsp27: lane 1, MDA-MB
231; lane 2, MCF7; lane 3, ZR-75; lane 4, T47D and lane 5, HUMA121. The
highest protein content occurred in ER-a(þ) cell lines. Molecular weight
marker: Triose phosphate isomerase: Mr 26600kDa.
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